<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(5)</volume><submitter>Nesaretnam K</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Basic research has indicated that tocotrienols have potent antiproliferative and proapoptotic effects that would be expected to reduce the effect of breast cancer.&lt;h4>Methods&lt;/h4>We conducted a double-blinded, placebo-controlled pilot trial to test the effectiveness of adjuvant tocotrienol therapy in combination with tamoxifen for five years in women with early breast cancer. Two-hundred-forty women, aged between 40-60 years, with either tumor node metastases (TNM) Stage I or II breast cancer and estrogen receptor (ER) positive tumors were non-randomly assigned to two groups. The intervention group received tocotrienol rich fraction (TRF) plus tamoxifen whilst the control group received placebo plus tamoxifen, for five years.&lt;h4>Results&lt;/h4>During the five years of stu</pubmed_abstract><journal>Breast cancer research : BCR</journal><pagination>R81</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3096974</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial.</pubmed_title><pmcid>PMC3096974</pmcid><pubmed_authors>Nesaretnam K</pubmed_authors><pubmed_authors>Selvaduray KR</pubmed_authors><pubmed_authors>Gomez PA</pubmed_authors><pubmed_authors>Abdul Razak G</pubmed_authors><pubmed_authors>Veerasenan SD</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial.</name><description>&lt;h4>Introduction&lt;/h4>Basic research has indicated that tocotrienols have potent antiproliferative and proapoptotic effects that would be expected to reduce the effect of breast cancer.&lt;h4>Methods&lt;/h4>We conducted a double-blinded, placebo-controlled pilot trial to test the effectiveness of adjuvant tocotrienol therapy in combination with tamoxifen for five years in women with early breast cancer. Two-hundred-forty women, aged between 40-60 years, with either tumor node metastases (TNM) Stage I or II breast cancer and estrogen receptor (ER) positive tumors were non-randomly assigned to two groups. The intervention group received tocotrienol rich fraction (TRF) plus tamoxifen whilst the control group received placebo plus tamoxifen, for five years.&lt;h4>Results&lt;/h4>During the five years of stu</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010</publication><modification>2025-04-18T23:31:43.13Z</modification><creation>2019-03-27T00:41:42Z</creation></dates><accession>S-EPMC3096974</accession><cross_references><pubmed>20929592</pubmed><doi>10.1186/bcr2726</doi></cross_references></HashMap>